SynthesisAntimicrobial agents and chemotherapy2014
A systematic review and meta-analyses show that carbapenem use and medical devices are the leading risk factors for carbapenem-resistant Pseudomonas aeruginosa.
Synthesis in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- In search of the best method to detect carriage of carbapenem-resistant Pseudomonas aeruginosa in humans: a systematic review.Annals of clinical microbiology and antimicrobials · 2024Pooled it
- Impact of COVID-19 pandemic on multidrug resistant gram positive and gram negative pathogens: A systematic review.Journal of infection and public health · 2023Pooled it
- A Systematic Review and Meta-analyses of the Clinical Epidemiology of Carbapenem-Resistant Enterobacteriaceae.Antimicrobial agents and chemotherapy · 2018Pooled it
- Acquired carbapenemase-producing organisms in North London: health inequalities and healthcare associations, 2016-2023.JAC-antimicrobial resistance · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Challenges and opportunities in the management of severe pneumonia. Key concepts from the Seventh Annual Meeting of Spanish Experts 2025.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2026Review
- Article
- Clinical gradient and predictors for stepwise resistance escalation of carbapenem-susceptible, carbapenem-resistant, and difficult-to-treat resistantFrontiers in cellular and infection microbiology · 2026Article
- Synergistic effects of colistin-based combinations against colistin and carbapenem-resistant Klebsiella pneumoniae isolated from nosocomial bloodstream infections.Scientific reports · 2025Article
- Pseudomonas aeruginosa carriage and associated risk factors in healthy individuals and patients from Rotterdam, Rome, and Jakarta.Scientific reports · 2025Article
- Predicting carbapenem-resistant Pseudomonas aeruginosa infection risk using XGBoost model and explainability.Scientific reports · 2025Article
- Sources and Transmission Routes of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Biofilm generation and antibiotic resistant profile of extensive and multidrug resistantHealth science reports · 2024Article
- Antibiotics-free compounds for managing carbapenem-resistant bacteria; a narrative review.Frontiers in pharmacology · 2024Review
- Description of a nationwide structure for monitoring nosocomial outbreaks of (highly resistant) microorganisms in the Netherlands: characteristics of outbreaks in 2012-2021.Antimicrobial resistance and infection control · 2023Article
- CarbapenemsHeliyon · 2023Article
- Carbapenem Use in the Last Days of Life: A Nationwide Korean Study.Antibiotics (Basel, Switzerland) · 2023Article
- Evaluation of the Use of Antimicrobial Therapy for Treating Diabetic Foot Infections in an Indonesia Referral Hospital: A Retrospective Cohort Study.Infection & chemotherapy · 2023Article
- New frontiers in healthcare environmental hygiene: thoughts from the 2022 healthcare cleaning forum.Antimicrobial resistance and infection control · 2023Article
- Risk factors and outcome associated with coinfection with carbapenem-resistantFrontiers in cellular and infection microbiology · 2023Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A systematic review and meta-analyses were performed to identify the risk factors associated with carbapenem-resistant Pseudomonas aeruginosa and to identify sources and reservoirs for the pathogen. A systematic search of PubMed and Embase databases from 1 January 1987 until 27 January 2012 identified 1,662 articles, 53 of which were included in a systematic review and 38 in a random-effects meta-analysis study. The use of carbapenem, use of fluoroquinolones, use of vancomycin, use of other antibiotics, having medical devices, intensive care unit (ICU) admission, having underlying diseases, patient characteristics, and length of hospital stay were significant risk factors in multivariate analyses. The meta-analyses showed that carbapenem use (odds ratio [OR] = 7.09; 95% confidence interval [CI] = 5.43 to 9.25) and medical devices (OR = 5.11; 95% CI = 3.55 to 7.37) generated the highest pooled estimates. Cumulative meta-analyses showed that the pooled estimate of carbapenem use was stable and that the pooled estimate of the risk factor "having medical devices" increased with time. We conclude that our results highlight the importance of antibiotic stewardship and the thoughtful use of medical devices in helping prevent outbreaks of carbapenem-resistant P. aeruginosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.